RecruitingNot ApplicableNCT06335160

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Sponsor

Tanta University

Enrollment

46 participants

Start Date

Apr 20, 2024

Study Type

INTERVENTIONAL

Conditions

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

Min Age: 18 YearsMax Age: 75 Years

Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)

\- Patients with severe UC
Significant liver and kidney function abnormalities
Diabetic patients
Patients with Colorectal cancer patients
Patients taking rectal or systemic steroids
Patients on immunosuppressants or biological therapies
Addiction to alcohol and / or drugs
Known allergy to the studied medications
History of complete or partial colectomy.
Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
Patients with other inflammatory diseases and active infection.
Patients with stressful condition (COPD, morbid obesity).
Patients with liver disease.
Patients with thrombocytopenia and neutropenia.
Patients with any type of seizures (case report for mebendazole induced convulsion).
Patients with renal disease (case report for mebendazole induced nephrotoxicity).
Patients with coagulation disorders.
Patients on metronidazole (to avoid Stevens-Johnson syndrome).
Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
Patients using antioxidants.
Pregnant and lactating females.
Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.

DRUGMebendazole

mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months

Tanta Unuversity

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06335160